Bezafibrate: lack of effect on creatinine excretion and muscular proteins.
The effect of bezafibrate (200 mg t.i.d.) on renal and, to some degree, on muscular function was studied in nine patients with primary hyperlipoproteinemia. No signs of a reduction in creatinine excretion or an increase in muscular proteins could be found serving as a possible explanation for the slight increase in serum creatinine observed in a bezafibrate long-term study in more than 1,000 patients. Further studies are necessary for clarification.
D001629:Bezafibrate; D002994:Clofibrate / Q000031:analogs & derivatives*; D002995:Clofibric Acid / Q000031:analogs & derivatives*; D003402:Creatine Kinase / Q000097:blood; D003404:Creatinine / Q000097:blood / Q000652:urine*; D005260:Female; D006801:Humans; D006951:Hyperlipoproteinemias / Q000503:physiopathology*; D000960:Hypolipidemic Agents; D007527:Isoenzymes; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged; D009124:Muscle Proteins / Q000378:metabolism*; D009132:Muscles / Q000187:drug effects / Q000503:physiopathology*; D009212:Myoglobinuria / Q000175:diagnosis
D000960:Hypolipidemic Agents; D007527:Isoenzymes; D009124:Muscle Proteins; D002995:Clofibric Acid; D003404:Creatinine; D003402:Creatine Kinase; D002994:Clofibrate; D001629:Bezafibrate